The Drug Controller General of India (DCGI) has given a green signal to global pharma firm Mylan for marketing its antiretroviral (ARV) drug Avonza in India as an alternative first-line treatment for HIV-AIDS affected people.
The drug is a fixed-dose combination comprised of Efavirenz (440 mg), Lamivudine (300 mg) and Tenofovir Disoproxil Fumarate Tablets (300 mg), as recommended by the World Health Organisation (WHO).
Commenting on the permission received from DCGI for marketing its drug, Mylan President Rajiv Malik said: “Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs.
The company is supplying Avonza to nearly 50 per cent patients affected with HIV-AIDS in more than 100 developing countries.
According to UNAIDS, India as on July 2017 witnessed 20 per cent decline in new HIV infections over the past few years. By 2016 end, the country stood at estimated 2.1 million people living with HIV-AIDS.